These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 31211166)

  • 1.
    Garrido A; Fairfoul G; Tolosa ES; Martí MJ; Green A;
    Ann Clin Transl Neurol; 2019 Jun; 6(6):1024-1032. PubMed ID: 31211166
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brain and Cerebrospinal Fluid α-Synuclein Real-Time Quaking-Induced Conversion Identifies Lewy Body Pathology in LRRK2-PD.
    Garrido A; Fairfoul G; Tolosa E; Marti MJ; Ezquerra M; Green AJE
    Mov Disord; 2023 Feb; 38(2):333-338. PubMed ID: 36471633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cerebrospinal fluid biomarkers and clinical features in leucine-rich repeat kinase 2 (LRRK2) mutation carriers.
    Vilas D; Shaw LM; Taylor P; Berg D; Brockmann K; Aasly J; Marras C; Pont-Sunyer C; Ríos J; Marek K; Tolosa E
    Mov Disord; 2016 Jun; 31(6):906-14. PubMed ID: 27041685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CSF total and oligomeric α-Synuclein along with TNF-α as risk biomarkers for Parkinson's disease: a study in LRRK2 mutation carriers.
    Majbour NK; Aasly JO; Hustad E; Thomas MA; Vaikath NN; Elkum N; van de Berg WDJ; Tokuda T; Mollenhauer B; Berendse HW; El-Agnaf OMA
    Transl Neurodegener; 2020 May; 9(1):15. PubMed ID: 32375873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between CSF alpha-synuclein seeding activity and genetic status in Parkinson's disease and dementia with Lewy bodies.
    Brockmann K; Quadalti C; Lerche S; Rossi M; Wurster I; Baiardi S; Roeben B; Mammana A; Zimmermann M; Hauser AK; Deuschle C; Schulte C; Waniek K; Lachmann I; Sjödin S; Brinkmalm A; Blennow K; Zetterberg H; Gasser T; Parchi P
    Acta Neuropathol Commun; 2021 Oct; 9(1):175. PubMed ID: 34717775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of α-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational study.
    Iranzo A; Fairfoul G; Ayudhaya ACN; Serradell M; Gelpi E; Vilaseca I; Sanchez-Valle R; Gaig C; Santamaria J; Tolosa E; Riha RL; Green AJE
    Lancet Neurol; 2021 Mar; 20(3):203-212. PubMed ID: 33609478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases.
    Mamais A; Raja M; Manzoni C; Dihanich S; Lees A; Moore D; Lewis PA; Bandopadhyay R
    Neurobiol Dis; 2013 Oct; 58():183-90. PubMed ID: 23747310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased peripheral inflammation in asymptomatic leucine-rich repeat kinase 2 mutation carriers.
    Dzamko N; Rowe DB; Halliday GM
    Mov Disord; 2016 Jun; 31(6):889-97. PubMed ID: 26917005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of macroautophagy related proteins in G2019S LRRK2 Parkinson's disease brains with Lewy body pathology.
    Mamais A; Manzoni C; Nazish I; Arber C; Sonustun B; Wray S; Warner TT; Cookson MR; Lewis PA; Bandopadhyay R
    Brain Res; 2018 Dec; 1701():75-84. PubMed ID: 30055128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alzheimer's disease tau is a prominent pathology in LRRK2 Parkinson's disease.
    Henderson MX; Sengupta M; Trojanowski JQ; Lee VMY
    Acta Neuropathol Commun; 2019 Nov; 7(1):183. PubMed ID: 31733655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpha-synuclein seeds in olfactory mucosa of patients with isolated REM sleep behaviour disorder.
    Stefani A; Iranzo A; Holzknecht E; Perra D; Bongianni M; Gaig C; Heim B; Serradell M; Sacchetto L; Garrido A; Capaldi S; Sánchez-Gómez A; Cecchini MP; Mariotto S; Ferrari S; Fiorini M; Schmutzhard J; Cocchiara P; Vilaseca I; Brozzetti L; Monaco S; Jose Marti M; Seppi K; Tolosa E; Santamaria J; Högl B; Poewe W; Zanusso G;
    Brain; 2021 May; 144(4):1118-1126. PubMed ID: 33855335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential Phospho-Signatures in Blood Cells Identify LRRK2 G2019S Carriers in Parkinson's Disease.
    Garrido A; Santamaría E; Fernández-Irigoyen J; Soto M; Simonet C; Fernández M; Obiang D; Tolosa E; Martí MJ; Padmanabhan S; Malagelada C; Ezquerra M; Fernández-Santiago R
    Mov Disord; 2022 May; 37(5):1004-1015. PubMed ID: 35049090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sleep Disorders in Parkinsonian and Nonparkinsonian LRRK2 Mutation Carriers.
    Pont-Sunyer C; Iranzo A; Gaig C; Fernández-Arcos A; Vilas D; Valldeoriola F; Compta Y; Fernández-Santiago R; Fernández M; Bayés A; Calopa M; Casquero P; de Fàbregues O; Jaumà S; Puente V; Salamero M; José Martí M; Santamaría J; Tolosa E
    PLoS One; 2015; 10(7):e0132368. PubMed ID: 26177462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LRRK2 modifies α-syn pathology and spread in mouse models and human neurons.
    Bieri G; Brahic M; Bousset L; Couthouis J; Kramer NJ; Ma R; Nakayama L; Monbureau M; Defensor E; Schüle B; Shamloo M; Melki R; Gitler AD
    Acta Neuropathol; 2019 Jun; 137(6):961-980. PubMed ID: 30927072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ultrasensitive Detection of Aggregated α-Synuclein in Glial Cells, Human Cerebrospinal Fluid, and Brain Tissue Using the RT-QuIC Assay: New High-Throughput Neuroimmune Biomarker Assay for Parkinsonian Disorders.
    Manne S; Kondru N; Hepker M; Jin H; Anantharam V; Lewis M; Huang X; Kanthasamy A; Kanthasamy AG
    J Neuroimmune Pharmacol; 2019 Sep; 14(3):423-435. PubMed ID: 30706414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parkinson's Disease-Associated LRRK2 Interferes with Astrocyte-Mediated Alpha-Synuclein Clearance.
    Streubel-Gallasch L; Giusti V; Sandre M; Tessari I; Plotegher N; Giusto E; Masato A; Iovino L; Battisti I; Arrigoni G; Shimshek D; Greggio E; Tremblay ME; Bubacco L; Erlandsson A; Civiero L
    Mol Neurobiol; 2021 Jul; 58(7):3119-3140. PubMed ID: 33629273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olfactory swab sampling optimization for α-synuclein aggregate detection in patients with Parkinson's disease.
    Bongianni M; Catalan M; Perra D; Fontana E; Janes F; Bertolotti C; Sacchetto L; Capaldi S; Tagliapietra M; Polverino P; Tommasini V; Bellavita G; Kachoie EA; Baruca R; Bernardini A; Valente M; Fiorini M; Bronzato E; Tamburin S; Bertolasi L; Brozzetti L; Cecchini MP; Gigli G; Monaco S; Manganotti P; Zanusso G
    Transl Neurodegener; 2022 Jul; 11(1):37. PubMed ID: 35902902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic value of cerebrospinal fluid alpha-synuclein seed quantification in synucleinopathies.
    Poggiolini I; Gupta V; Lawton M; Lee S; El-Turabi A; Querejeta-Coma A; Trenkwalder C; Sixel-Döring F; Foubert-Samier A; Pavy-Le Traon A; Plazzi G; Biscarini F; Montplaisir J; Gagnon JF; Postuma RB; Antelmi E; Meissner WG; Mollenhauer B; Ben-Shlomo Y; Hu MT; Parkkinen L
    Brain; 2022 Apr; 145(2):584-595. PubMed ID: 34894214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LRRK2 G2019S Mutation Inhibits Degradation of α-Synuclein in an In Vitro Model of Parkinson's Disease.
    Hu D; Niu JY; Xiong J; Nie SK; Zeng F; Zhang ZH
    Curr Med Sci; 2018 Dec; 38(6):1012-1017. PubMed ID: 30536063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapidly progressive multiple system atrophy in a patient carrying LRRK2 G2019S mutation.
    Carrer T; Bonato G; Sandre M; Emmi A; Campagnolo M; Musso G; Carecchio M; Parchi P; Antonini A
    Neurol Sci; 2024 Jan; 45(1):309-313. PubMed ID: 37752324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.